LYRA THERAPEUTICS INC

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

12 May 2023 07:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

09 May 2023 16:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

25 Apr 2023 07:59:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

29 Mar 2023 16:06:12 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

27 Feb 2023 07:59:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

06 Feb 2023 07:56:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 Jan 2023 18:42:43 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present at Upcoming Investor Conferences

09 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

21 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

20 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

13 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

09 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

17 Aug 2021 07:35:13 By Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments

09 Aug 2021 16:05:01 By Nasdaq GlobeNewswire

Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9

26 Jul 2021 16:05:00 By Nasdaq GlobeNewswire

Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference

12 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

30 Jun 2021 07:00:00 By Nasdaq GlobeNewswire